NEW YORK, May 21 (GenomeWeb News) - Lynx Therapeutics has signed a service contract with the National Institute of Mental Health to study gene expression in the brain, the company said today.
Under the agreement, with the NIMH's Genes, Cognition, and Psychosis program, Lynx will use its Massively Parallel Signature Sequencing technology to analyze gene expression in a region of the brain cortex that has been implicated in schizophrenia.
Lynx will receive payments for its services on samples provided by NIMH.